# A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Study · id `cardio:ct-nct02025907` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02025907](<https://clinicaltrials.gov/study/NCT02025907>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02025907

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

## Technical summary

Registry record NCT02025907. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-09-02.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 218 participants (enrolled count; ClinicalTrials.gov record NCT02025907, source copy `cardio:ctgov-nct02025907-2016-10-31`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT02025907, source copy `cardio:ctgov-nct02025907-2016-10-31`, retrieved 2026-10-26)
- Primary completion: 2015-09 (actual) (ClinicalTrials.gov record NCT02025907, source copy `cardio:ctgov-nct02025907-2016-10-31`, retrieved 2026-10-26)
- Completion: 2015-09 (actual) (ClinicalTrials.gov record NCT02025907, source copy `cardio:ctgov-nct02025907-2016-10-31`, retrieved 2026-10-26)
- Results first posted: 2016-09-02 (ClinicalTrials.gov record NCT02025907, source copy `cardio:ctgov-nct02025907-2016-10-31`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; France; Germany (ClinicalTrials.gov record NCT02025907, source copy `cardio:ctgov-nct02025907-2016-10-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02025907-2016-10-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Canagliflozin, 100 mg
- Intervention (Drug): Canagliflozin, 300 mg
- Intervention (Drug): Placebo
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

## Provenance

Content hash: d4fb2f609530e88c234411e75fb647d54edb6d1121d445082ea5c9ed1fff3b84
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
